Light Therapy for Chemotherapy Induced Peripheral Neuropathy in Childhood Cancer Survivors
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age5+
SponsorYale University
About this trial
The purpose of this study is to determine feasibility and acceptability of a six-week at-home light therapy protocol in childhood cancer survivors, to identify facilitators and barriers to implementing this intervention, and to measure signs and symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN) at baseline and following completion of the at-home light therapy protocol.
Eligibility criteria
Qualifiers
History of childhood cancer (<21 years of age at diagnosis)
Current age five years or older (due to availability of validated measures for CIPN in this age group)
History of exposure to vinca alkaloid, platinum, or other chemotherapeutic agent that can cause CIPN
CIPN as assessed by a trained physical therapist defined as a score of four or higher on the ped-mTNS (for survivors <18 years old at evaluation), or the mTNS (for survivors 18 years or older at evaluation)
Disqualifiers
Currently Pregnant or lactating (by patient report, at initiation or at any point of the study)
Inability to sit still for at least 15 minutes
Diagnosis of neuropathy prior to cancer treatment
Active cancer diagnosis or cancerous skin lesion
Trial design
Treatments tested in this trial
- Anodyne Therapy System
Treatment groups
20 Participants
are divided into 1 treatment groupLocations
2Yale New Haven Health Smilow York Street Hospital06520, New HavenConnecticut, United States
Yale New Haven Health Park Avenue Medical Center06611, TrumbullConnecticut, United States
Sponsors and collaborators
Yale University
Lead sponsor
Rally Foundation for Childhood Cancer Research
Collaborator
Source ClinicalTrials.gov